ENERGY-GLOBE-FOUNDATION
1.12.2022 12:25:34 CET | Business Wire | Press release
In an extremely exciting ceremony on November 30 in Vienna at the world's most important environmental award, the world winners for sustainability were chosen in the 5 categories, Earth, Fire, Water, Air and Youth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005435/en/
From left to right - Freya Burton (LanzaTech – Winner Category AIR from China), Sarah Alexander (nurture.farm, AgTech Startup – Winner Category EARTH from India), Karl Boyce (ARC Power – Winner Category FIRE from Rwanda), Roberta Dixon-Valk (Take 3 for the Sea – Winner Category YOUTH from Australia), Rodrigo Oliveira (Eco Panplas – Winner Category WATER from Brazil) (Photo: Business Wire)
For more than 20 years, the Energy Globes have been awarded annually. In total, over 30,000 sustainable projects have been submitted, proposing innovative solutions to environmental problems. This was confirmed by high-ranking experts in a panel discussion before the ceremony, among them Nobel Laureate Prof. Mohan Munasinghe: “There is no shortage of solutions to our current crises, as the many projects entered for the Energy Globe have demonstrated impressively. It is important to inform people and economic players worldwide of these solutions, and to motivate them to join in their implementation.”
To achieve this, the unique www.checkpoint.eco portal providing advice on energy efficiency was introduced.
In the category “Earth”, projects from Ethiopia, Czech Republic and India were nominated, showing how vast areas of land can be made fertile again through reforestation, or replacing plastic-fillers with biological waste and fungi. The winner came from India, where a bio-enzyme prevented the burning off of millions of hectares of stubblefields and increased soil fertility at the same time.
The winning project in the “Fire” category came from Ruanda, where green electricity is being made available and affordable for everyone. The nominated projects from Portugal and Switzerland presented green electricity using sea wave power, and an energy saving of 90% for data storage in data centres, respectively.
A project from Brazil, which keeps 17 billion litres of drinking water clean annually through the collection and recycling of oil bottles, won the “Water” category. Runners-up from Slovenia and Jordan showed how filters in washing machines prevent microplastic fibres from getting into the wastewater, and how wastewater may be purified even in remote areas.
In the “Air” category, the winning project from China recycles CO2, thus manufacturing new fuels. Projects from Austria and Canada suggested ways of producing hydrogen independently and saving energy in air-condition systems while simultaneously improving air quality.
Winner in the ”Youth” category was a project from Australia, which is helping to educate young people in environmental matters in 129 countries.
At the end, a special prize for climate-friendly cooking, which affects billions of people, was awarded.
For details, see www.energyglobe.info
A new cryptocurrency for sustainability, SGCf (Sustainable Globe Coin fraction) for short, was also introduced for the first time. Thanks to a newly developed algorithm, production of the SGCf is energy-efficient, and the value of the currency is generated through zero-emission projects, resulting in financial incentives as well as investments in low-carbon, sustainable economic activities. The coin may be stored in digital wallets as well as converted into other currencies on www.xglober.com. Each Energy Globe World Award winner received EUR 3,000 Euro in SGCf.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
